WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE
Retrieved on:
Wednesday, January 19, 2022
Cannabidiol, Forward-looking statement, Research, News, CBG, Inflammation, Trevor Peters, Biotechnology, Apache Hadoop, Signum Biosciences, WLLW, COVID-19, Ageing, CBD, Willow Garage, Intellectual property, CBGA, Female, Volunteering, Government, Nhek Dim, Cannabinoid, Health, Red, View, Industry, Skin, Company, Food, Serum, Multimedia, Collagen, Hand, Male, TSX, 3D, Failure, Elastin, B2C, Trial of the century, Risk, Pharmaceutical industry, Carding, Molecule, Willow, BC
The results of the Willow Study were published in Molecules, a leading international,peer-reviewed, open access journal that can be found here at https://www.mdpi.com/1420-3049/27/2/491/htm .
Key Points:
- The results of the Willow Study were published in Molecules, a leading international,peer-reviewed, open access journal that can be found here at https://www.mdpi.com/1420-3049/27/2/491/htm .
- "Willow's FutureGrownTMCBG continues to exhibit great promise as an exciting new skincare ingredient", said Trevor Peters, Willow's President and Chief Executive Officer.
- "We are excited to share the results of our in vitro and clinical work with our stakeholders and proud to have it published in a peer reviewed scientific journal, the first of its kind for CBG.
- Lastly, the Willow Study is the first to report the clinical effectiveness of topically applied CBG, demonstrating that a 0.1% CBG serum reduces inflammation, redness, and improves the skin barrier significantly better than a placebo.